Justin SaeksMolecular DiagnosticsA look at how COVID-19 testing varies by world regionWorldwide demand for COVID tests has materialized rapidly from zero and is on course to become a $1.3 billion market in the first half of 2020, according to Kalorama Information's report on molecular diagnostic markets in the COVID-19 era.July 26, 2020Regulatory ApprovalWorld market outlook: COVID-19 testing evolves rapidly, lessons sink inWorldwide, COVID-19 testing volume was on target to grow 25%-30% from May to June. New products and services are continually being introduced, and regulatory approvals have been growing and expanding to include more types of tests, samples, and sample collection methods.June 28, 2020InfectiousCOVID-19 testing presents learning curve for all involvedAs of April 22, around 4.5 million COVID-19 diagnostic tests had been performed in the U.S., which began large-scale testing in early March. There is still some uncertainty regarding what level of testing is needed in the long term, partly due to unknowns about the chances for success of countries' efforts to stop the disease's spread. Other unknown variables include the current disease prevalence and the schedules for rolling back shelter-in-place orders.April 23, 2020Health TopicsMolecular testing and COVID-19: Where are we now?Countries have been trying to apply the lessons learned in the regions that were hit first. China appears to have dramatically slowed the disease, and one of the key aspects of that effort has been large-scale diagnostic testing.Tests that received EUAs as of March 24March 25, 2020Page 1 of 1Top StoriesLiquid BiopsyOraSure, nRichDx to offer products for researchers developing urine-based liquid biopsy assaysThe firms noted that their products use first-void urine, which is enriched in biomarkers suitable for molecular analysis by people researching sexually-transmitted infections, human papillomavirus, and early stage cancers.Regulatory ApprovalBiolytical Laboratories nabs Health Canada authorization for HIV-1/2 syphilis antibody testNon Small Cell Lung CancerAmoyDx PLC Panel gets Japanese approval as companion diagnostic for NSCLCSequencingIllumina NGS software to enable tertiary analysis for oncology, rare diseaseMergers & AcquisitionsCalibre Scientific acquires U.K. provider of scientific equipment, supplies, services
